Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 8, 2011, Pages 1290-1297

  Yu, Lianzhen ^a   Aa, Jiye ^b   Xu, Jin ^a   Sun, Min ^c   Qian, Sixuan ^a   Cheng, Liping ^d   Yang, Shuping ^a   Shi, Ruihua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Suzhou Medical College of Soochow University   (China)

^d China   (China)

Author keywords

Gas chromatography time of flight mass spectrometry; Gastric cancer; Metabolic phenotype

Indexed keywords

1 MONOHEXADECANOYLGLYCEROL; 11 EICOSENOIC ACID; 2 HYDROXYBUTYRATE DEHYDROGENASE; ASPARAGINE; AZELAIC ACID; BIOLOGICAL MARKER; CREATININE; GAMMA TOCOPHEROL; GLUTAMIC ACID; ORNITHINE; PYROGLUTAMIC ACID; THREONATE; UNCLASSIFIED DRUG; URATE;

ADULT; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER STAGING; CHRONIC ATROPHIC GASTRITIS; CHRONIC SUPERFICIAL GASTRITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; FATTY ACID METABOLISM; FEMALE; GAS CHROMATOGRAPHY; GASTRIC DYSPLASIA; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; OXIDATIVE STRESS; PHENOTYPE; PRECANCER; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER; STOMACH DISEASE; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 79960438225     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06724.x     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
2. Yang L. Incidence and mortality of gastric cancer in China. World J. Gastroenterol. 2006; 12: 17-20.
3. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48: 3554-60.
4. Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment. Pharmacol. Ther. 2002; 16 (Suppl. l2): 198-203.
5. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 1054-6.
6. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134: 714-6.
7. Clayton TA, Lindon JC, Cloarec O etal. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-7.
8. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabolomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002; 1: 153-61.
9. Denkert C, Budczies J, Weichert W etal. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008; 7: 72-86.
10. Chan EC, Koh PK, Mal M etal. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009; 8: 352-61.
11. Hirayama A, Kami K, Sugimoto M etal. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009; 69: 4918-25.
12. Sreekumar A, Poisson LM, Rajendiran TM etal. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-14.
13. Yang J, Xu G, Zheng Y etal. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and atocirrhosis diseases. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004; 813: 59-65.
14. Odunsi K, Wollman RM, Alnbrosone CB etal. Detection of epithelial ovarian cancer using 1H-NMR-based metabnomies. Int. J. Cancer 2005; 113: 782-8.
15. Denkert C, Budczies J, Kind T etal. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and Varian borderline tumors. Cancer Res. 2006; 66: 10795-804.
16. Bullinger D, Fröhlich H, Klaus F etal. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal. Chim. Acta 2008; 618: 29-34.
17. A J, Trygg J, Gullberg J etal. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal. Chem. 2005; 77: 8086-94.
18. Jonsson P, Johansson AI, Gullberg J etal. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal. Chem. 2005; 77: 5635-42.
19. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J. Proteome Res. 2007; 6: 469-79.
20. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi- and Megavariate Data Analysis: Principles and Applications. Sweden: Umeatrics Academy: Umetrics AB, 2001; 102-5.
21. Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978; 20: 397-405.
22. Janssen YM, Van Houten B, Borm PJ, Moosman BT. Cell and tissue responses to oxidative damage. Lab. Invest. 1993; 69: 261-74.
23. Atherton JC. The clinical relevance of strain types of Helicobacter pylori. Gut 1997; 40: 701-3.
24. Naito Y, Yoshikawa T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radic. Biol. Med. 2002; 33: 323-36.
25. Farinati F, Cardin R, Degan P etal. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut 1998; 42: 351-6.
26. Beevi SS, Rasheed MH, Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin. Chim. Acta 2007; 375: 119-23.
27. Kasapović J, Pejić S, Todorović A, Stojiljković V, Pajović SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem. Funct. 2008; 26: 723-30.
28. Raghavamenon AC, Garelnabi M, Babu S, Aldrich A, Litvinov D, Parthasarathy S. Alpha-tocopherol is ineffective in preventing the decomposition of preformed lipid peroxides and may promote the accumulation of toxic aldehydes: a potential explanation for thefailure of antioxidants to affect human atherosclerosis. Antioxid. Redox. Signal. 2009; 11: 1237-48.
29. Schallreuter KU, Wood JM. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett. 1987; 36: 297-305.
30. Lee GJ, Chung HW, Lee KH, Ahn HS. Antioxidant vitamins and lipid peroxidation in patient with cervical intraepiththelial neoplasia. J. Korean Med. Sci. 2005; 20: 267-72.
31. Feng J-F, Li S-L. Correlation between oxidative stress and trace elements in blood of patients with cancer. Chin. J. Clin. Rehabil. 2006; 10: 187-90.
32. Cascino A, Muscaritoli M, Cangiano C etal. Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res. 1995; 15: 507-10.
33. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu. Rev. Nutr. 2007; 27: 19-40.
34. Kannan R, Lyon I, Baker N. Dietary control of lipogenesis in vivo in host tissues and tumors of mice bearing Ehrlich ascites carcinoma. Cancer Res. 1980; 40: 4606-11.
35. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 1984; 247 (1 Pt 2): R146-53.
36. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U.S.A. 1981; 78: 6858-62.
37. Burgaz S, Torun M, Yardim S, Sargin H, Orman MN, Ozdamar NY. Serum carotenoids and uric acid levels in relation to cancer. J. Clin. Pharm. Ther. 1996; 21: 331-6.